Dosing information Usual Adult Dose of Bydureon BCisefor Diabetes Type 2: Extended-release: Initial dose - 2 mg subcutaneously once every 7 days (weekly) -May administer any time of day, with or without meals
No claims are made regarding the safety, efficacy, or suitability for therapeutic use
A variety of post-translational modifications, such as phosphorylation, ubiquitination, methylation, and palmitoylation, are present in ZDHHC, and they have important roles in regulating ZDHHC enzyme stability, localization, and activity
This makes it useful not only for injury recovery but also for managing chronic inflammatory conditions
A phase III study of pafolacianine injection (OTL38) for intraoperative imaging of folate receptorpositive ovarian cancer (Study 006)